DiaSorin

DiaSorin is an Italian in vitro diagnostics company headquartered in Saluggia, Vercelli, Italy, founded in 1968, that develops immunoassays and molecular diagnostic tests primarily for hospital and reference laboratory applications, with particular strength in infectious disease serology, endocrinology, and specialty testing. DiaSorin's LIAISON automated immunoassay analyzer platform is widely deployed in hospital labs for high-throughput quantitative serology, with assays for vitamins D2 and D3 (LIAISON 25-OH Vitamin D TOTAL assay), thyroid hormones, cardiac biomarkers, celiac disease antibodies, and TORCH infections being particularly adopted. Their vitamin D assay portfolio has been especially influential, as DiaSorin was among the first companies to commercialize a robust 25-hydroxyvitamin D total assay, enabling the population-level research that defined vitamin D insufficiency epidemiology and the reference ranges now used globally. DiaSorin Molecular, acquired through the purchase of Gen-Probe technologies, develops transcription-mediated amplification (TMA) and multiplex PCR molecular assays for STIs, respiratory viruses, and sexually transmitted diseases run on the PANTHER and PANTHER Fusion platforms. For research purposes, DiaSorin's broad menu of validated assay kits allows clinical researchers to process large biobank cohorts on automated platforms with high reproducibility. Their CLIA-compliant LIAISON XL and LIAISON XS systems provide scalable automation from medium to high-volume labs. DiaSorin's collaborations with academic medical centers for biomarker validation studies support their assay development pipeline.